KOPRANNSEKopran Limited· PharmaceuticalsMinimalNeutral
Announced Fri, 16 May · 16:36 IST

Kopran Limited has informed the Exchange about Copy of Newspaper Publication

KOPRAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Kopran Limited has submitted copies of the newspaper advertisement of its audited consolidated financial results for Q4 and the full year ended March 31, 2025, published in Business Standard and Tarun Bharat on May 16, 2025, as required under SEBI Listing Regulations. The results show consolidated total income from operations of Rs. 62,960.44 lakhs for FY25 vs Rs. 61,459.18 lakhs in FY24 (a modest ~2.4% YoY rise), but net profit after tax fell sharply to Rs. 3,855.19 lakhs from Rs. 5,095.62 lakhs (~24% drop YoY). Q4 was even weaker, with net profit nearly halving to Rs. 967.73 lakhs from Rs. 1,862.01 lakhs a year ago, and Q4 revenue declining to Rs. 17,236.31 lakhs from Rs. 18,608.12 lakhs. EPS for the full year stood at Rs. 7.99 (vs Rs. 10.57 in FY24). The Board has recommended a 30% dividend (Rs. 3.00 per share on face value of Rs. 10), subject to shareholder approval.

Likely market impact

The profit decline — particularly the sharp Q4 fall in both revenue and net profit despite a small rise in full-year income — suggests margin pressure and weaker end-of-year performance, which could weigh on short-term sentiment. However, the declared dividend of Rs. 3 per share offers some income support for shareholders.